Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ: ATYR )

3.040 -0.080 (-2.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 675,414
Open 3.170
Bid (Size) 3.050 (2)
Ask (Size) 3.100 (38)
Prev. Close 3.120
Today's Range 3.010 - 3.250
52wk Range 1.420 - 3.680
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
From aTyr Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+67.03%
+67.03%
1 Month
+74.71%
+74.71%
3 Month
+61.70%
+61.70%
6 Month
+67.03%
+67.03%
1 Year
+67.03%
+67.03%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Participate in September Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024
Via InvestorPlace
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Research Study with Stanford Medicine
From aTyr Pharma, Inc.
Via GlobeNewswire
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.